Worth reading
59In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
1768
¥ millionWording
Conditional
How definitive the wording is.Items stated in the management plan
FormulatedNet Sales+13.9%
基準 63,223Target72,000million
Operating profit+67.2%
基準 2,632Target4,400million
Operating profit margin+1.9pt
基準 4.2Target6.1%
Each line is the climb from the baseline the document states to the target it sets. The slope is scaled against the largest climb in this document. For metrics expressed as percentages, differences are shown in percentage points (pt).The increase shown by the dotted line is calculated from the two reported figures because the company did not provide the amount of growth.
What happened to the previous plan¥100 billion → ¥63.2 billion（△36.8%）-36.8%Calculated from the two disclosed figures
Key initiatives
01적극ive development of new businesses
02Thorough strengthening of the financial base
03Ongoing M&A business
04Growth business, "Drug Discovery": Grow into a pharmaceutical company based on antibody technology
05Development of a new drug for the designated intractable disease CADASIL
06Growth business, "Textiles": New hybrid fiber ovoveil (オボヴェール)
07Growth business, "Agriculture": Address the global agricultural crisis through biostimulants (BS)
08Core business: Accelerate expansion in Europe through the safety data for PharmaGABA®
09Core business, "Overseas Business": Human resources strategy to accelerate global growth
10Core business, "明治薬品": Make the CMO business a strong profit base through a new plant
11Core business, "BtoC": Stabilize and turn operating cash flow positive
12M&A strategy: Agreement to acquire 100% of the shares of マリン・プロフーズ
13Create a new growth area, the medical food business
Segment targetSegment Drug Discovery / Target Early approval of a CADASIL treatment in 2030; peak sales of ¥2 billion after approval / Timing 2030 and after approval, Segment Fibers / Target ovoveil revenue of ¥3 billion / Timing 2031, Segment Agribusiness / Target Biostimulant revenue of ¥1 billion / Timing 2031, Segment 明治薬品 and CMO business / Target Revenue of ¥5 billion / Timing Five years from now, Segment BtoC / Target Maintain annual profit of ¥4 billion / Timing During the plan period
Non-financial targetsIndicator Approval of a CADASIL treatment / Target Early approval in 2030 / Timing 2030, Indicator Energy storage capacity of a new electrode material derived from eggshell membranes / Target Retain at least 90% after 10,000 charging cycles / Timing Not disclosed
Risks identified by the company
Forecasts, outlooks and strategies may differ materially from expectations due to changes in the economic and business environments
Progress in the drug discovery pipeline, licensing agreements and approvals are not guaranteed
| Item | Details |
|---|---|
| Plan name | Medium-Term Management Plan 2029, "1K Project: SPRING Strategy" |
| Plan period | Three years from the fiscal year ending July 2027 through the fiscal year ending July 2029 |
| Progress against the plan | Formulated |
| Sales Target | ¥63,223 million → ¥72,000 million（+13.9%） |
| Operating profit target | ¥2,632 million → 4,400 (¥4.1 billion in the main text)（+67.2% (based on ¥4,400 million in the attached materials)） |
| Operating profit margin target | 4.2% → 6.1%（+45.2%） |
| Segment target | Segment Drug Discovery / Target Early approval of a CADASIL treatment in 2030; peak sales of ¥2 billion after approval / Timing 2030 and after approval, Segment Fibers / Target ovoveil revenue of ¥3 billion / Timing 2031, Segment Agribusiness / Target Biostimulant revenue of ¥1 billion / Timing 2031, Segment 明治薬品 and CMO business / Target Revenue of ¥5 billion / Timing Five years from now, Segment BtoC / Target Maintain annual profit of ¥4 billion / Timing During the plan period |
| Non-financial targets | Indicator Approval of a CADASIL treatment / Target Early approval in 2030 / Timing 2030, Indicator Energy storage capacity of a new electrode material derived from eggshell membranes / Target Retain at least 90% after 10,000 charging cycles / Timing Not disclosed |
| Key initiatives | 적극ive development of new businesses, Thorough strengthening of the financial base, Ongoing M&A business, Growth business, "Drug Discovery": Grow into a pharmaceutical company based on antibody technology, Development of a new drug for the designated intractable disease CADASIL, Growth business, "Textiles": New hybrid fiber ovoveil (オボヴェール), Growth business, "Agriculture": Address the global agricultural crisis through biostimulants (BS), Core business: Accelerate expansion in Europe through the safety data for PharmaGABA®, Core business, "Overseas Business": Human resources strategy to accelerate global growth, Core business, "明治薬品": Make the CMO business a strong profit base through a new plant, Core business, "BtoC": Stabilize and turn operating cash flow positive, M&A strategy: Agreement to acquire 100% of the shares of マリン・プロフーズ, Create a new growth area, the medical food business |
| Results under the previous plan | ¥100 billion → ¥63.2 billion（△36.8%） |
| Risks identified | Forecasts, outlooks and strategies may differ materially from expectations due to changes in the economic and business environments, Progress in the drug discovery pipeline, licensing agreements and approvals are not guaranteed |
| Date of board resolution | 16 October 2026 |
| Publication date | 16 October 2026 |
Items this document does not state (12)
Net income targetROE targetROIC targetPayout ratio / DOE policyTreasury share acquisition policyCost of capitalSelf-assessment of PBR and share priceTotal investment planInvestment amount by sectorPlan assumptionsReason for revision or withdrawalSize of the Target Market
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To strengthen the profitability of existing businesses, develop new growth areas, strengthen the financial base and operating cash flow, and create new growth areas through M&A.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.